复星医药(02196.HK):实体瘤治疗新药获药品临床试验申请受理
格隆汇4月27日丨复星医药(02196.HK)公布,近日,公司控股子公司重庆复创医药研究有限公司(以下简称"复创医药")收到《受理通知书》(受理号:CXHL2000185 国、CXHL2000186 国),其研制的 FCN-011 胶囊(以下简称"该新药")用于实体瘤治疗获国家药品监督管理局(以下简称"国家药监局")临床试验注册审评受理。
该新药为集团(即公司及控股子公司/单位,下同)自主研发的创新型小分子化学药物,拟主要用于实体瘤治疗。截至公告日,在中国大陆境内尚无与该新药同类型产品上市。截至 2020年3月,集团现阶段针对该新药累计研发投入为人民币约 2,139 万元(未经审计)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.